The NCI (National Cancer Institute) highlighted two photo-immunotherapy (PIT) approaches that employ antibodies conjugated to phthalocyanine dye IRDye 700DX (IR700). Continue reading
Tag Archives: CD25+
Immatics and MD Anderson Collaborate on IL-21 for Cancer Immunotherapy
Immatics, a German biotechnology company has established a subsidiary in Houston, TX to collaborate with MD Anderson on overcoming some of the limitations to the adoptive T cell therapies now in the immuno-oncology pipeline. The collaboration covers the use of cytokine IL-21 to expand high-quality T cell batches, particularly those generated by CAR-T (chimeric antigen receptor T-cell) and related approaches. Continue reading
Novel mutated antigens from Tumor Infiltrating Lymphocytes from long-term melanoma responders
Tumor Infiltrating Lymphocytes (TILs) are cytotoxic T-cells that are found in tumors. They serve to destroy cancer, or at least keep cancer at bay. Adoptive immunotherapy, Continue reading